Literature DB >> 17537932

Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method.

Bert van Klingeren1, Mirjam Dessens-Kroon, Tridia van der Laan, Kristin Kremer, Dick van Soolingen.   

Abstract

Accurate drug susceptibility testing (DST) for Mycobacterium tuberculosis is highly important for both therapy guidance and surveillance of drug resistance. Although liquid medium DST methods are used increasingly and seem most efficient and fast, the high costs hamper widespread implementation. In addition, an inability to check the colony morphology of the growing bacteria is a disadvantage of these methods. Moreover, these methods discriminate only between susceptibility and resistance and do not determine the MIC. In this paper, we describe a low-cost, reproducible, high-throughput, proportional absolute concentration DST method. The method uses a concentration series of antituberculosis drugs, including pyrazinamide in 7H10 medium, distributed semiautomatically in 25-well plates. The performance of this 25-well DST method was evaluated by the World Health Organization and the International Union against Tuberculosis and Lung Disease in 10 rounds of proficiency testing regarding sensitivity, specificity, efficiency, reproducibility, and predictive value for resistance and susceptibility. The performance of the method for these characteristics was 100% for isoniazid and from 96 to 100% for rifampin, 91 to 100% for streptomycin, and 85 to 100% for ethambutol. The method was 100% reproducible for all four drugs. The levels of drug resistance and the MIC distributions for the first-line antituberculosis drugs were determined for all 7,956 M. tuberculosis strains isolated in The Netherlands from 1998 to 2005 and amounted to 7.5% for isoniazid, 1.4% for rifampin, 8.5% for streptomycin, and 1.0% for ethambutol. Pyrazinamide testing was successful for 7,026 (88.3%) of the isolates and showed a resistance level of 0.8%.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17537932      PMCID: PMC1951260          DOI: 10.1128/JCM.00244-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Preparation of tuberculosis susceptibility testing mediums by means of impregnated disks.

Authors:  L G Wayne; I Krasnow
Journal:  Am J Clin Pathol       Date:  1966-06       Impact factor: 2.493

2.  Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.

Authors:  G Canetti; W Fox; A Khomenko; H T Mahler; N K Menon; D A Mitchison; N Rist; N A Smelev
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

3.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

4.  Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  S H Siddiqi; J P Libonati; G Middlebrook
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

5.  A comparison of various measures of sensitivity of M. tubercolosis to pyrazinamide.

Authors:  S P Tripathy; D A Mitchison; N G Nair; S Radhakrishna; S Subbammal
Journal:  Tubercle       Date:  1970-12

6.  Insertion element IS1081-associated restriction fragment length polymorphisms in Mycobacterium tuberculosis complex species: a reliable tool for recognizing Mycobacterium bovis BCG.

Authors:  D van Soolingen; P W Hermans; P E de Haas; J D van Embden
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

7.  Amplification of a species-specific DNA fragment of Mycobacterium tuberculosis and its possible use in diagnosis.

Authors:  P Del Portillo; L A Murillo; M E Patarroyo
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

8.  Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method.

Authors:  Claudio Scarparo; Paolo Ricordi; Giuliana Ruggiero; Paola Piccoli
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

9.  Use of various genetic markers in differentiation of Mycobacterium bovis strains from animals and humans and for studying epidemiology of bovine tuberculosis.

Authors:  D van Soolingen; P E de Haas; J Haagsma; T Eger; P W Hermans; V Ritacco; A Alito; J D van Embden
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

10.  Radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis in egg-yolk-enriched BACTEC 12A medium.

Authors:  C L Woodley; R W Smithwick
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

View more
  39 in total

1.  In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.

Authors:  J A Dijkstra; T van der Laan; O W Akkerman; M S Bolhuis; W C M de Lange; J G W Kosterink; T S van der Werf; J W C Alffenaar; D van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  Clinical Mycobacterium conspicuum isolation from two immunocompetent patients in The Netherlands.

Authors:  J van Ingen; M J Boeree; F S Stals; C C M Pitz; J J C M Rooijmans-Rietjens; A G M van der Zanden; P N R Dekhuijzen; D van Soolingen
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

3.  Transmission classification model to determine place and time of infection of tuberculosis cases in an urban area.

Authors:  G de Vries; H W M Baars; M M G G Sebek; N A H van Hest; J H Richardus
Journal:  J Clin Microbiol       Date:  2008-10-08       Impact factor: 5.948

4.  Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.

Authors:  J W C Alffenaar; P M de Vries; G J Luijckx; D van Soolingen; T S van der Werf; R van Altena
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

5.  Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.

Authors:  Suha Kadura; Nicholas King; Maria Nakhoul; Hongya Zhu; Grant Theron; Claudio U Köser; Maha Farhat
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

6.  Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.

Authors:  Natasha Van't Boveneind-Vrubleuskaya; Tatiana Seuruk; Kai van Hateren; Tridia van der Laan; Jos G W Kosterink; Tjip S van der Werf; Dick van Soolingen; Susan van den Hof; Alena Skrahina; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.

Authors:  R van Altena; J A Dijkstra; M E van der Meer; J F Borjas Howard; J G W Kosterink; D van Soolingen; T S van der Werf; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  New approach for drug susceptibility testing: monitoring the stress response of mycobacteria.

Authors:  Ronald J Rieder; Zhihui Zhao; Boris Zavizion
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

9.  Otomastoiditis caused by Mycobacterium abscessus, The Netherlands.

Authors:  Jakko van Ingen; Frank Looijmans; Piet Mirck; Richard Dekhuijzen; Martin Boeree; Dick van Soolingen
Journal:  Emerg Infect Dis       Date:  2010-01       Impact factor: 6.883

10.  Nontuberculous mycobacteria infection and tumor necrosis factor-alpha antagonists.

Authors:  Reinout M Swart; Jakko van Ingen; Dick van Soolingen; Rob Slingerland; Willem D H Hendriks; Jan G den Hollander
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.